Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Common Equity (2016 - 2025)

Historic Common Equity for Adma Biologics (ADMA) over the last 14 years, with Q3 2025 value amounting to $431.2 million.

  • Adma Biologics' Common Equity rose 8594.42% to $431.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $431.2 million, marking a year-over-year increase of 8594.42%. This contributed to the annual value of $349.0 million for FY2024, which is 15813.8% up from last year.
  • Adma Biologics' Common Equity amounted to $431.2 million in Q3 2025, which was up 8594.42% from $398.3 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Common Equity ranged from a high of $431.2 million in Q3 2025 and a low of $100.4 million during Q3 2022
  • Moreover, its 5-year median value for Common Equity was $146.8 million (2023), whereas its average is $193.0 million.
  • In the last 5 years, Adma Biologics' Common Equity tumbled by 1103.35% in 2023 and then soared by 15813.8% in 2024.
  • Adma Biologics' Common Equity (Quarter) stood at $141.2 million in 2021, then increased by 7.65% to $152.0 million in 2022, then dropped by 11.03% to $135.2 million in 2023, then surged by 158.14% to $349.0 million in 2024, then increased by 23.54% to $431.2 million in 2025.
  • Its Common Equity was $431.2 million in Q3 2025, compared to $398.3 million in Q2 2025 and $373.4 million in Q1 2025.